Company Profile

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and Nasdaq (ticker symbol: PMN). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical and Medicine Industry (3741)

Contact Information

Investor Relations
Stern Investor Relations
Suzanne Messere
Managing Director
T: 212-698-9901
suzanne.messere@sternir.com

Company Contact
ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada
T: 416-847-6898
F: 416-847-6899